What should I avoid while taking Chlorprothixene 15mg tablets?

Avoid alcohol. Take with food. Food reduces irritation. (Source: DrugBank, licensed under CC BY-NC 4.0)

Do I need a prescription for Chlorprothixene 15mg tablets?

Chlorprothixene 15mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Chlorprothixene 15mg tablets?

Chlorprothixene 15mg tablets is the generic name. It is available under brand names including: Truxal 15mg tablets. (Source: NHS dm+d — Actual Medicinal Products)

Chlorprothixene 15mg tablets

Prescription only

Requires a prescription from a doctor or prescriber

Tablet

15mg

Oral

Chlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class.

Active ingredients:

Chlorprothixene

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC N05AF03

Check interactions for Chlorprothixene

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Chlorprothixene

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Chlorprothixene

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Chlorprothixene

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

1 branded products available

1 productsShow details

1 products

Possibly available on the UK marketRestricted supplyDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Chlorprothixene on the MHRA register

Truxal 15mg tablets

Imported (Denmark)

None

Imported

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Therapeutically similar medicines

10 similarShow details

Chlorprothixene 50mg tablets

Tablet

50mg

Same therapeutic group

Flupentixol 1mg/5ml oral solution

Oral solution

1mg/5ml

Same therapeutic group

Zuclopenthixol 20mg/ml oral drops

Other

20mg

Same therapeutic group

Flupentixol 500micrograms/5ml oral solution

Oral solution

5ml

Same therapeutic group

Flupentixol 500micrograms/5ml oral suspension

Oral suspension

5ml

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

Clinical guidelines and formulary information

British National Formulary

Chlorprothixene

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Chlorprothixene

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

39389311000001104

dm+d ID

39389311000001104

VTM (Virtual Therapeutic Moiety)

775218006

VMP (Virtual Medicinal Product)

39389311000001104

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

N05AF03

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

1 found

Half-life

8 to 12 hours

Mechanism

Chlorprothixene blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors…

Food interactions

2 warnings

Human targets

11 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

Incomplete bioavailability.

Half-life

8 to 12 hours

8 to 12 hours

Metabolism

Hepatic

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Withdrawn

Small molecule

About this compound

Chlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.

Properties:

solid

Avg. mass: 315.86 Da

DrugBank indication

For treatment of psychotic disorders (e.g. schizophrenia) and of acute mania occuring as part of bipolar disorders.

Also known as(98)

Alpha-Chlorprothixene

Chlorprothixen

Chlorprothixene

Chlorprothixine

Chlorprotixen

Chlorprotixene

Chlorprotixine

Chlothixen

Dosage forms(5)

Tablet, film coated (Oral) — 15 mg/1

Tablet, film coated (Oral) — 50 mg/1

Tablet, film coated (Oral) — 90 mg/1

Tablet, film coated (Oral) — 15 MG

Tablet, film coated (Oral) — 50 MG

Molecular properties(18)

Drug interactions(1294)

Known interactions with other medications. Always consult a healthcare professional.

Buprenorphine

Moderate

DB00921

Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.

Check this interaction

Doxylamine

Moderate

DB00366

Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.

Check this interaction

Dronabinol

Moderate

DB00470

Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.

Check this interaction

Droperidol

Moderate

DB00450

Droperidol may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.

Check this interaction

Hydrocodone

Moderate

DB00956

Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.

Check this interaction

Magnesium sulfate

Moderate

DB00653

The therapeutic efficacy of Chlorprothixene can be increased when used in combination with Magnesium sulfate.

Check this interaction

Methotrimeprazine

Moderate

DB01403

Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.

Check this interaction

Metyrosine

Moderate

DB00765

Chlorprothixene may increase the sedative activities of Metyrosine.

Check this interaction

Minocycline

Moderate

DB01017

Minocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.

Check this interaction

Mirtazapine

Moderate

DB00370

Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.

Check this interaction

Nabilone

Moderate

DB00486

Nabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.

Check this interaction

Orphenadrine

Moderate

DB01173

Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.

Check this interaction

Paraldehyde

Moderate

DB09117

Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.

Check this interaction

Perampanel

Moderate

DB08883

Perampanel may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.

Check this interaction

Rotigotine

Moderate

DB05271

Chlorprothixene may increase the sedative activities of Rotigotine.

Check this interaction

Rufinamide

Unknown severity

DB06201

The risk or severity of adverse effects can be increased when Rufinamide is combined with Chlorprothixene.

Check this interaction

Sodium oxybate

Moderate

DB09072

Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.

Check this interaction

Suvorexant

Moderate

DB09034

Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.

Check this interaction

Tapentadol

Moderate

DB06204

Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.

Check this interaction

Thalidomide

Moderate

DB01041

Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.

Check this interaction

Zolpidem

Moderate

DB00425

Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.

Check this interaction

Aclidinium

Unknown severity

DB08897

The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Aclidinium.

Check this interaction

Mianserin

Moderate

DB06148

Mianserin may increase the anticholinergic activities of Chlorprothixene.

Check this interaction

Mirabegron

Unknown severity

DB08893

The risk or severity of urinary retention can be increased when Chlorprothixene is combined with Mirabegron.

Check this interaction

Potassium chloride

Unknown severity

DB00761

The risk or severity of gastrointestinal ulceration can be increased when Chlorprothixene is combined with Potassium chloride.

Check this interaction

Pramlintide

Unknown severity

DB01278

The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Chlorprothixene.

Check this interaction

Secretin porcine

Moderate

DB09527

The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Chlorprothixene.

Check this interaction

Tiotropium

Unknown severity

DB01409

The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tiotropium.

Check this interaction

Topiramate

Unknown severity

DB00273

The risk or severity of hyperthermia and oligohydrosis can be increased when Chlorprothixene is combined with Topiramate.

Check this interaction

Umeclidinium

Unknown severity

DB09076

The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Umeclidinium.

Check this interaction

Amisulpride

Moderate

DB06288

Chlorprothixene may increase the antipsychotic activities of Amisulpride.

Check this interaction

Methylphenidate

Unknown severity

DB00422

The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methylphenidate.

Check this interaction

Dexmethylphenidate

Unknown severity

DB06701

The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dexmethylphenidate.

Check this interaction

Metoclopramide

Unknown severity

DB01233

The risk or severity of adverse effects can be increased when Metoclopramide is combined with Chlorprothixene.

Check this interaction

Quinagolide

Moderate

DB09097

The therapeutic efficacy of Quinagolide can be decreased when used in combination with Chlorprothixene.

Check this interaction

Sulpiride

Moderate

DB00391

Chlorprothixene may increase the antipsychotic activities of Sulpiride.

Check this interaction

Benzylpenicilloyl polylysine

Moderate

DB00895

Chlorprothixene may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent.

Check this interaction

Betahistine

Moderate

DB06698

The therapeutic efficacy of Betahistine can be decreased when used in combination with Chlorprothixene.

Check this interaction

Methadone

Unknown severity

DB00333

The risk or severity of adverse effects can be increased when Methadone is combined with Chlorprothixene.

Check this interaction

Lithium citrate

Moderate

DB14507

Lithium citrate may increase the neurotoxic activities of Chlorprothixene.

Check this interaction

Lithium hydroxide

Moderate

DB14506

Lithium hydroxide may increase the neurotoxic activities of Chlorprothixene.

Check this interaction

Mequitazine

Moderate

DB01071

Chlorprothixene may increase the arrhythmogenic activities of Mequitazine.

Check this interaction

Glycopyrronium

Unknown severity

DB00986

The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Glycopyrronium.

Check this interaction

Dicoumarol

Unknown severity

DB00266

The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dicoumarol.

Check this interaction

Phenindione

Unknown severity

DB00498

The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Phenindione.

Check this interaction

Warfarin

Unknown severity

DB00682

The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Warfarin.

Check this interaction

Phenprocoumon

Unknown severity

DB00946

The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Phenprocoumon.

Check this interaction

Acenocoumarol

Unknown severity

DB01418

The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Acenocoumarol.

Check this interaction

4-hydroxycoumarin

Unknown severity

DB03410

The risk or severity of adverse effects can be increased when Chlorprothixene is combined with 4-hydroxycoumarin.

Check this interaction

Coumarin

Unknown severity

DB04665

The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Coumarin.

Check this interaction

Showing 50 of 1294 interactions

Food & lifestyle interactions

Avoid Alcohol

Avoid alcohol.

Take With Food

Take with food. Food reduces irritation.

Toxicity & overdose

Symptoms of overdose include difficulty in breathing (severe), dizziness (severe), drowsiness (severe), muscle trembling, jerking, stiffness, or uncontrolled movements (severe), small pupils, unusual excitement, and unusual tiredness or weakness (severe).

How it works

Mechanism of action

Chlorprothixene blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.

Pharmacodynamics

Chlorprothixene is a typical antipsychotic drug of the thioxanthine class. It has a low antipsychotic potency (half to 2/3 of chlorpromazine). Chlorprothixene has not thoroughly demonstrated an antidepressant or analgesic effect but it has demonstrated antiemetic effects. It is used in the treatment of nervous, mental, and emotional conditions. Improvement in such conditions is thought to result from the effect of the medicine on nerve pathways in specific areas of the brain. Chlorprothixene has a similar side effect profile to chlorpromazine, though allergic side effects and liver damage are less frequent.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Incomplete bioavailability.

Half-life

8 to 12 hours

Metabolism

Hepatic

Drug targets(11)

Proteins and enzymes this drug interacts with in the body

D(2) dopamine receptor

BE0000756

DRD2

antagonist

Specific functiondopamine binding

Cellular location

Cell membrane

General function & pharmacology

Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase .
PMID:21645528
Positively regulates postnatal regression of retinal hyaloid vessels via suppression of VEGFR2/KDR activity, downstream of OPN5 (By similarity)

D(1A) dopamine receptor

BE0000020

DRD1

antagonist

Specific functionarrestin family protein binding

Cellular location

Cell membrane

General function & pharmacology

Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase

D(3) dopamine receptor

BE0000581

DRD3

antagonist

Specific functiondopamine neurotransmitter receptor activity, coupled via Gi/Go

Cellular location

Cell membrane

General function & pharmacology

Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation

5-hydroxytryptamine receptor 2A

BE0000451

HTR2A

antagonist

Specific function1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding

Cellular location

Cell membrane

General function & pharmacology

G-protein coupled receptor for 5-hydroxytryptamine (serotonin) .
PMID:1330647 PMID:18703043 PMID:19057895 PMID:21645528 PMID:22300836 PMID:35084960 PMID:38552625

Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD) .
PMID:28129538 PMID:35084960
Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors .
PMID:28129538 PMID:35084960
HTR2A is coupled to G(q)/G(11) G alpha proteins and activates phospholipase C-beta, releasing diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) second messengers that modulate the activity of phosphatidylinositol 3-kinase and promote the release of Ca(2+) ions from intracellular stores, respectively .
PMID:18703043 PMID:28129538 PMID:35084960

Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways .
PMID:28129538 PMID:35084960
Affects neural activity, perception, cognition and mood .
PMID:18297054
Plays a role in the regulation of behavior, including responses to anxiogenic situations and psychoactive substances. Plays a role in intestinal smooth muscle contraction, and may play a role in arterial vasoconstriction (By similarity)

Histamine H1 receptor

BE0000442

HRH1

antagonist

Specific functionhistamine receptor activity

Cellular location

Cell membrane

General function & pharmacology

G-protein-coupled receptor for histamine, a biogenic amine that functions as an immune modulator and a neurotransmitter .
PMID:33828102 PMID:8280179
Through the H1 receptor, histamine mediates the contraction of smooth muscles and increases capillary permeability due to contraction of terminal venules. Also mediates neurotransmission in the central nervous system and thereby regulates circadian rhythms, emotional and locomotor activities as well as cognitive functions (By similarity)

Transporters(1)

Proteins that transport this drug across cell membranes

ATP-dependent translocase ABCB1

BE0001032

ABCB1

inhibitor

Specific functionABC-type xenobiotic transporter activity

Cellular location

Cell membrane

General function & pharmacology

Translocates drugs and phospholipids across the membrane .
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548

Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218

ATC classification(1 code)

ATC N05AF03

Affected organisms(1)

Humans and other mammals

International brands(3)

Salt forms(1)

Chlorprothixene hydrochloride(DBSALT002973)

Experimental properties(3)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Chlorprothixene

DB01239

CAS number

113-59-7

UNII (FDA)

9S7OD60EWP

InChI Key (molecular fingerprint)

WSPOMRSOLSGNFJ-AUWJEWJLSA-N

Additional database identifiers

ChEBI

50931

PubChem Compound

667466

PubChem Substance

46508957

KEGG Compound

C07953

KEGG Drug

D00790

ChemSpider

580849

BindingDB

50240514

PharmGKB

PA164781400

Therapeutic Targets Database

DAP000833

Wikipedia

Chlorprothixene

ChEMBL

CHEMBL908

ZINC

ZINC000000001137

RxCUI

2406

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3023

GenAtlas

DRD2

GeneCards

DRD2

GenBank Gene Database

M30625

GenBank Protein Database

181432

IUPHAR

215

Guide to Pharmacology

215

UniProtKB

P14416

UniProt Accession

DRD2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3020

GenAtlas

DRD1

GeneCards

DRD1

GenBank Gene Database

X55760

GenBank Protein Database

30397

IUPHAR

214

Guide to Pharmacology

214

UniProtKB

P21728

UniProt Accession

DRD1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3024

GenAtlas

DRD3

GeneCards

DRD3

GenBank Gene Database

U32499

GenBank Protein Database

927342

IUPHAR

216

Guide to Pharmacology

216

UniProtKB

P35462

UniProt Accession

DRD3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5293

GenAtlas

HTR2A

GeneCards

HTR2A

GenBank Gene Database

S42168

GenBank Protein Database

36431

IUPHAR

Guide to Pharmacology

UniProtKB

P28223

UniProt Accession

5HT2A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5182

GenAtlas

HRH1

GeneCards

HRH1

GenBank Gene Database

Z34897

GenBank Protein Database

510296

IUPHAR

262

Guide to Pharmacology

262

UniProtKB

P35367

UniProt Accession

HRH1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5286

GenAtlas

HTR1A

GeneCards

HTR1A

GenBank Gene Database

M28269

GenBank Protein Database

189928

IUPHAR

Guide to Pharmacology

UniProtKB

P08908

UniProt Accession

5HT1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5287

GenAtlas

HTR1B

GeneCards

HTR1B

GenBank Gene Database

D10995

GenBank Protein Database

219679

IUPHAR

Guide to Pharmacology

UniProtKB

P28222

UniProt Accession

5HT1B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5289

GenAtlas

HTR1D

GeneCards

HTR1D

GenBank Gene Database

M89955

GenBank Protein Database

177772

IUPHAR

Guide to Pharmacology

UniProtKB

P28221

UniProt Accession

5HT1D_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5291

GenAtlas

HTR1E

GeneCards

HTR1E

GenBank Gene Database

M91467

GenBank Protein Database

177774

IUPHAR

Guide to Pharmacology

UniProtKB

P28566

UniProt Accession

5HT1E_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5292

GenAtlas

HTR1F

GeneCards

HTR1F

GenBank Gene Database

L05597

GenBank Protein Database

307420

IUPHAR

Guide to Pharmacology

UniProtKB

P30939

UniProt Accession

5HT1F_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5293

GenAtlas

HTR2A

GeneCards

HTR2A

GenBank Gene Database

S42168

GenBank Protein Database

36431

IUPHAR

Guide to Pharmacology

UniProtKB

P28223

UniProt Accession

5HT2A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5294

GenAtlas

HTR2B

GeneCards

HTR2B

GenBank Gene Database

X77307

GenBank Protein Database

475198

IUPHAR

Guide to Pharmacology

UniProtKB

P41595

UniProt Accession

5HT2B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5295

GenAtlas

HTR2C

GeneCards

HTR2C

GenBank Gene Database

M81778

GenBank Protein Database

338028

IUPHAR

Guide to Pharmacology

UniProtKB

P28335

UniProt Accession

5HT2C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5297

GenAtlas

HTR3A

GeneCards

HTR3A

GenBank Gene Database

D49394

GenBank Protein Database

681914

IUPHAR

373

Guide to Pharmacology

373

UniProtKB

P46098

UniProt Accession

5HT3A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5298

GeneCards

HTR3B

Guide to Pharmacology

374

UniProtKB

O95264

UniProt Accession

5HT3B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:24003

GeneCards

HTR3C

UniProtKB

Q8WXA8

UniProt Accession

5HT3C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:24004

GeneCards

HTR3D

UniProtKB

Q70Z44

UniProt Accession

5HT3D_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:24005

GeneCards

HTR3E

UniProtKB

A5X5Y0

UniProt Accession

5HT3E_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5299

GenAtlas

HTR4

GeneCards

HTR4

GenBank Gene Database

Y12505

GenBank Protein Database

2661757

IUPHAR

Guide to Pharmacology

UniProtKB

Q13639

UniProt Accession

5HT4R_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5301

GenAtlas

HTR6

GeneCards

HTR6

GenBank Gene Database

L41147

GenBank Protein Database

1162924

IUPHAR

Guide to Pharmacology

UniProtKB

P50406

UniProt Accession

5HT6R_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5302

GenAtlas

HTR7

GeneCards

HTR7

GenBank Gene Database

U68487

GenBank Protein Database

1857143

IUPHAR

Guide to Pharmacology

UniProtKB

P34969

UniProt Accession

5HT7R_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1950

GenAtlas

CHRM1

GeneCards

CHRM1

GenBank Gene Database

X52068

GenBank Protein Database

34451

IUPHAR

Guide to Pharmacology

UniProtKB

P11229

UniProt Accession

ACM1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1951

GenAtlas

CHRM2

GeneCards

CHRM2

GenBank Gene Database

M16404

GenBank Protein Database

177990

IUPHAR

Guide to Pharmacology

UniProtKB

P08172

UniProt Accession

ACM2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1952

GenAtlas

CHRM3

GeneCards

CHRM3

GenBank Gene Database

X15266

GenBank Protein Database

32324

IUPHAR

Guide to Pharmacology

UniProtKB

P20309

UniProt Accession

ACM3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1953

GenAtlas

CHRM4

GeneCards

CHRM4

GenBank Gene Database

M16405

GenBank Protein Database

61970253

IUPHAR

Guide to Pharmacology

UniProtKB

P08173

UniProt Accession

ACM4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1954

GenAtlas

CHRM5

GeneCards

CHRM5

GenBank Gene Database

M80333

GenBank Protein Database

177988

IUPHAR

Guide to Pharmacology

UniProtKB

P08912

UniProt Accession

ACM5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:40

GenAtlas

ABCB1

GeneCards

ABCB1

GenBank Gene Database

M14758

GenBank Protein Database

307180

Guide to Pharmacology

768

UniProtKB

P08183

UniProt Accession

MDR1_HUMAN

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated about 1 month ago(4 Mar 2026)

Back to medicines

Chlorprothixene 15mg tablets

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

British National Formulary

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Metabolism

Clinical essentials

Pharmacology

Deep science
12

Chemical identifiers

Chlorprothixene

Additional database identifiers

DrugBank citations

Chlorprothixene 15mg tablets

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

Medicines like this

Guidance (NICE / BNF)

British National Formulary

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Metabolism

Clinical essentials

Pharmacology

Deep science12

Chemical identifiers

Chlorprothixene

Additional database identifiers

DrugBank citations

Deep science
12